Patent intelligence · US
US 12533358
Methods of treatment with elinzanetant
Methods of treatment with elinzanetant
Patent details — US 12533358
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 27, 2026
- Expiration
- Jan 22, 2046
- Applicant
- BAYER CONSUMER CARE AG [CH]
- CPC classes
- A61K 31/ 5383 A I, A61K/315383, A61P 15/ 12 A I, A61P/1512
Quick answer
US 12533358 (Methods of treatment with elinzanetant) is held by BAYER CONSUMER CARE AG [CH]. Status: granted. Granted Jan 27, 2026. Expires Jan 22, 2046 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BAYER CONSUMER CARE AG [CH]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 5383 A I, A61K/315383, A61P 15/ 12 A I, A61P/1512
Frequently asked questions
What is US patent 12533358?
US 12533358 (Methods of treatment with elinzanetant) is held by BAYER CONSUMER CARE AG [CH]. Status: granted. Granted Jan 27, 2026. Expires Jan 22, 2046 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12533358?
BAYER CONSUMER CARE AG [CH] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews.
When does US 12533358 expire?
Our index shows an expiration date of Jan 22, 2046 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.